CoChat

Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study

Open access

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

BACKGROUND CH5126766 (also known as VS-6766, and previously named RO5126766), a novel MEK-pan-RAF inhibitor, has shown antitumour activity across various solid tumours; however, its initial development was limited by toxicity. We aimed to investigate the safety and toxicity profile of intermittent dosing schedules of CH5126766, and the antitumour activity of this drug in patients with solid tumours and multiple myeloma harbouring RAS-RAF-MEK pathway mutations. METHODS We did a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study at the Royal Marsden National Health Service Foundation Trust (London, UK). Patients were eligible for the study if they were aged 18 years or older, had cancers that were refractory to conventional treatment or for which no conventional therapy existed, and if they had a WHO performance status score of 0 or 1. For the dose-escalation phase, eligible patients had histologically or cytologically confirmed advanced or metastatic solid tumours. For the basket dose-expansion phase, eligible patients had advanced or metastatic solid tumours or multiple myeloma harbouring RAS-RAF-MEK pathway mutations. During the dose-escalation phase, we evaluated three intermittent oral schedules (28-day cycles) in patients with solid tumours: (1) 4·0 mg or 3·2 mg CH5126766 three times per week; (2) 4·0 mg CH5126766 twice per week; and (3) toxicity-guided dose interruption schedule, in which treatment at the recommended phase 2 dose (4·0 mg C…

Overview

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(20)30464-2

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 30 references

Research works printed but not linked: 1

  1. Canon, 2019, The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity, Nature, 575, 217, 10.1038/s41586-019-1694-1 · DOI · Paper page

Cited by

See all 78

Metadata

Authors
Guo, C., Chénard-Poirier, M., Roda, D., de Miguel, M., Harris, S. J., Candilejo, I. M., Sriskandarajah, P., Xu, W., Scaranti, M., Constantinidou, A., King, J., Parmar, M., Turner, A. J., Carreira, S., Riisnaes, R., Finneran, L., Hall, E., Ishikawa, Y., Nakai, K., Tunariu, N., Basu, B., Kaiser, M., Lopez, J. S., Minchom, A., de Bono, J. S., & Banerji, U.
Affiliations
  • Royal Marsden NHS Foundation Trust (GB)
  • Institute of Cancer Research (GB)
  • Chugai Pharmaceutical Co., Ltd. (Japan) (JP)
  • University of Cambridge (GB)
Corresponding author
Banerji, Udai
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2020-11
Volume
21
Issue
11
Pages
1478-1488
ISSN
1470-2045 (ISSN-L)
OpenAlex
W3097863157
Cited by
78
References
30
Citations by year
2026: 14 · 2025: 12 · 2024: 14 · 2023: 8 · 2022: 15 · 2021: 14 · 2020: 1
FWCI
3.16
Type
journal article
Language
en
Update notices
erratum (2021-02-01)
Open access
Licence
  • cc-by-nc-nd
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • Apollo (University of Cambridge) (submittedVersion, cc-by-nc-nd)
  • Apollo
Funders
  • Chugai Pharmaceutical
  • NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
  • National Institute for Health Research
  • Cancer Research UK
  • Institute of Cancer Research
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords
RAF/MEK inhibitors, intermittent dosing, multiple myeloma, solid tumors, dose escalation, dose expansion, safety and toxicity, antitumour activity, recommended phase 2 dose, refractory cancer, oral anticancer drugs
MeSH terms
Administration, Oral, Adult, Aged, Coumarins, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Multiple Myeloma, ras Proteins, MAP Kinase Signaling System, Protein Kinase Inhibitors, raf Kinases, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study. https://app.cochat.ai/papers/10.1016/s1470-2045(20)30464-2
The paper
Guo, C., Chénard-Poirier, M., Roda, D., de Miguel, M., Harris, S. J., Candilejo, I. M., Sriskandarajah, P., Xu, W., Scaranti, M., Constantinidou, A., King, J., Parmar, M., Turner, A. J., Carreira, S., Riisnaes, R., Finneran, L., Hall, E., Ishikawa, Y., Nakai, K., . . . Banerji, U. (2020). Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(20)30464-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.